TY - JOUR
T1 - Chemotherapy targeted to tumor vasculature
AU - Arap, Wadih
AU - Pasqualini, Renata
AU - Ruoslahti, Erkki
PY - 1998
Y1 - 1998
N2 - Vasculature-targeted chemotherapy-the destruction of tumor blood vessels with cytotoxic agents-makes use of biochemical differences between angiogenic and resting blood vessels. This approach may minimize or eliminate some of the problems associated with conventional solid-tumor targeting, such as poor tissue penetration and drug resistance. Experiments with antiangiogenic and thrombotic factors have shown that eliminating tumor blood supply has dramatic antitumor effects in mice. Targeting chemotherapeutic agents to the tumor vasculature combines the blood vessel destruction with the usual antitumor activities of the drug, resulting in increased efficacy and reduced toxicity in experiments with tumor-bearing mice. Human clinical trials, which are soon to follow, will determine the final value of this approach.
AB - Vasculature-targeted chemotherapy-the destruction of tumor blood vessels with cytotoxic agents-makes use of biochemical differences between angiogenic and resting blood vessels. This approach may minimize or eliminate some of the problems associated with conventional solid-tumor targeting, such as poor tissue penetration and drug resistance. Experiments with antiangiogenic and thrombotic factors have shown that eliminating tumor blood supply has dramatic antitumor effects in mice. Targeting chemotherapeutic agents to the tumor vasculature combines the blood vessel destruction with the usual antitumor activities of the drug, resulting in increased efficacy and reduced toxicity in experiments with tumor-bearing mice. Human clinical trials, which are soon to follow, will determine the final value of this approach.
UR - http://www.scopus.com/inward/record.url?scp=0031785722&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031785722&partnerID=8YFLogxK
U2 - 10.1097/00001622-199811000-00014
DO - 10.1097/00001622-199811000-00014
M3 - Review article
C2 - 9818236
AN - SCOPUS:0031785722
SN - 1040-8746
VL - 10
SP - 560
EP - 565
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 6
ER -